After the Ablation: StimCardio, Wearable Neuromodulation and the Next AF Outcome Gap
Dr. Dereck Mush, MD, MBAMetis MedTech
Investment and strategic advisory platform
- Stages
- Series A
- Cheque size
- Based in
- North America
- Focus
- Medical devices, Cardiovascular
Metis MedTech is led by CEO and founder John Slump. StimCardio's October 29, 2026 release identifies Metis as the lead investor in its $30 million Series A and Slump as a StimCardio board member.
Supports medical device companies through financing, commercialization and strategic advisory.
Notable investments
- StimCardio Medical
Investors at similar stages
- 7wireVentures
Venture fund
- Andreessen Horowitz Bio + Health
Venture fund
- Bessemer Venture Partners
Venture fund
- Catalyst Health Ventures
Venture fund
- CommonSpirit Ventures
Health system venture investor
- CVS Health Ventures
Corporate venture
Related on The Signal
Dr. Dereck Mush, MD, MBA
DTD 2026 Munich: The HealthTech Operator's Field Guide
Dr. Dereck Mush, MD, MBA
Growth-Accommodating Medtech: How Expandable Scaffolds Disrupt Congenital Surgical Cycles
Dr. Dereck Mush, MD, MBA
The Universal Telemetry Layer: Why Implicity's Cross-Vendor Remote Cardiac Platform Raised $40M
Dr. Dereck Mush, MD, MBAKeep exploring